0001683168-23-002830.txt : 20230501
0001683168-23-002830.hdr.sgml : 20230501
20230501185957
ACCESSION NUMBER: 0001683168-23-002830
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230428
FILED AS OF DATE: 20230501
DATE AS OF CHANGE: 20230501
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Climaco John M
CENTRAL INDEX KEY: 0001546797
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39126
FILM NUMBER: 23875854
MAIL ADDRESS:
STREET 1: PO BOX 326
CITY: PARK CITY
STATE: UT
ZIP: 84060
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: CNS Pharmaceuticals, Inc.
CENTRAL INDEX KEY: 0001729427
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 822318545
STATE OF INCORPORATION: NV
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 2100 WEST LOOP SOUTH
STREET 2: SUITE 900
CITY: HOUSTON
STATE: TX
ZIP: 77027
BUSINESS PHONE: 1-800-946-9185
MAIL ADDRESS:
STREET 1: 2100 WEST LOOP SOUTH
STREET 2: SUITE 900
CITY: HOUSTON
STATE: TX
ZIP: 77027
4
1
ownership.xml
X0407
4
2023-04-28
0
0001729427
CNS Pharmaceuticals, Inc.
CNSP
0001546797
Climaco John M
C/O CNS PHARMACEUTICALS, INC.
100 WEST LOOP SOUTH, SUITE 900
HOUSTON
TX
77027
1
1
0
0
Chief Executive Officer
0
Common Stock
2023-04-28
4
M
0
1250
A
46260
D
Restricted Stock Units
2023-04-28
4
M
0
1250
D
Common Stock
1250
60201
D
Restricted stock units convert into common stock on a one-for-one basis.
On April 28, 2022, the reporting person received 20,000 restricted stock units vesting as follows, subject to the grantee's continued service to the Company on each vesting date, (i) 25% of the grant will vest in four equal annual installments over 4 years; (ii) 25% of the grant will vest if within 24 months from issuance the average the closing price of the Issuer common stock over a ten trading day period exceeds $2.00 (subject to pro rata adjustment for stock splits or similar events); (iii) 25% of the grant will vest if within 36 months from issuance the average the closing price of the Issuer common stock over a ten trading day period exceeds $4.00 (subject to pro rata adjustment for stock splits or similar events); and (iv) 25% of the grant will vest if within 24 months from issuance the Issuer achieves positive interim, clinical data as determined by its Board of Directors.
/s/ John M. Climaco
2023-05-01